Compare Lupin with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs AJANTA PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN AJANTA PHARMA LUPIN/
AJANTA PHARMA
 
P/E (TTM) x 46.9 28.5 165.0% View Chart
P/BV x 4.3 7.9 54.6% View Chart
Dividend Yield % 0.5 0.4 112.6%  

Financials

 LUPIN   AJANTA PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-20
AJANTA PHARMA
Mar-19
LUPIN/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs8821,422 62.0%   
Low Rs505898 56.3%   
Sales per share (Unadj.) Rs339.4233.5 145.3%  
Earnings per share (Unadj.) Rs-5.944.0 -13.5%  
Cash flow per share (Unadj.) Rs15.552.2 29.7%  
Dividends per share (Unadj.) Rs6.009.00 66.7%  
Dividend yield (eoy) %0.90.8 111.5%  
Book value per share (Unadj.) Rs276.7255.1 108.5%  
Shares outstanding (eoy) m453.0088.02 514.7%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.05.0 41.1%   
Avg P/E ratio x-116.626.4 -442.1%  
P/CF ratio (eoy) x44.822.2 201.6%  
Price / Book Value ratio x2.54.5 55.1%  
Dividend payout %-100.920.5 -492.9%   
Avg Mkt Cap Rs m314,201102,081 307.8%   
No. of employees `00018.36.8 269.1%   
Total wages/salary Rs m29,8684,307 693.5%   
Avg. sales/employee Rs Th8,400.63,022.6 277.9%   
Avg. wages/employee Rs Th1,632.0633.4 257.7%   
Avg. net profit/employee Rs Th-147.2569.1 -25.9%   
INCOME DATA
Net Sales Rs m153,74820,554 748.0%  
Other income Rs m4,838211 2,294.9%   
Total revenues Rs m158,58520,765 763.7%   
Gross profit Rs m24,8495,664 438.7%  
Depreciation Rs m9,702721 1,346.0%   
Interest Rs m3,63012 31,291.4%   
Profit before tax Rs m16,3555,143 318.0%   
Minority Interest Rs m40-   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,5711,273 909.0%   
Profit after tax Rs m-2,6943,870 -69.6%  
Gross profit margin %16.227.6 58.6%  
Effective tax rate %70.824.8 285.8%   
Net profit margin %-1.818.8 -9.3%  
BALANCE SHEET DATA
Current assets Rs m154,13211,812 1,304.8%   
Current liabilities Rs m92,2523,776 2,442.9%   
Net working cap to sales %40.239.1 102.9%  
Current ratio x1.73.1 53.4%  
Inventory Days Days8277 106.1%  
Debtors Days Days12982 158.4%  
Net fixed assets Rs m89,08214,398 618.7%   
Share capital Rs m906175 516.5%   
"Free" reserves Rs m124,46122,277 558.7%   
Net worth Rs m125,36722,452 558.4%   
Long term debt Rs m17,9337 271,709.1%   
Total assets Rs m249,83926,962 926.6%  
Interest coverage x5.5444.3 1.2%   
Debt to equity ratio x0.10 48,660.6%  
Sales to assets ratio x0.60.8 80.7%   
Return on assets %0.414.4 2.6%  
Return on equity %-2.117.2 -12.5%  
Return on capital %8.723.0 38.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,45010,682 481.7%   
Fx outflow Rs m19,4702,102 926.3%   
Net fx Rs m31,9808,580 372.7%   
CASH FLOW
From Operations Rs m14,6883,748 391.9%  
From Investments Rs m11,070-2,228 -496.9%  
From Financial Activity Rs m-8,906-1,475 603.9%  
Net Cashflow Rs m16,85345 37,284.3%  

Share Holding

Indian Promoters % 46.6 73.8 63.1%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 1.6 729.0%  
FIIs % 31.9 7.6 419.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 17.0 59.4%  
Shareholders   98,259 20,968 468.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   PROCTER & GAMBLE HEALTH  CIPLA  ASTRAZENECA PHARMA  AUROBINDO PHARMA  STERLING BIOTECH  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 7, 2021 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS